Biologische Heilmittel Heel Gmbh
🚨 Critical Risk
FEI: 3002806504 • Baden-Baden, Baden-Wurttemberg • GERMANY
FEI Number
3002806504
Location
Baden-Baden, Baden-Wurttemberg
Country
GERMANYAddress
Dr.-Reckeweg-Str. 2-4, , Baden-Baden, Baden-Wurttemberg, Germany
Critical Risk
FDA Import Risk Assessment
This firm has an extensive history of FDA import refusals with severe violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
DRUG GMPS
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods used in and controls used for the manufacture, processing, packing, or holding of drugs and other products do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
NO ENGLISH
Required label or labeling appears to not be in English in violation of 21 C.F.R. 201.15(c)(1).
DIRECTIONS
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.
NEW VET DR
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act in that it appears to be a new animal drug that is unsafe within the meaning of Section 512(a) of the Federal Food, Drug, and Cosmetic Act as it is not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing, and no investigational new animal drug exemption applies.
WARNINGS
It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users.
DR QUALITC
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the drug appears to be represented as not being recognized in an official compendium and appears its strength differs from or its quality or purity falls below, that which it purports or is represented to possess.
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
DIRSEXMPT
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
DRUG NAME
The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient.
STERILITY
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to have been prepared, packed or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health.
LIST INGRE
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(i)(2) of the FD&C Act in that it is fabricated from two or more ingredients and the label fails to bear the common or usual name of each such ingredient and/or the article purports to be a beverage containing vegetable or fruit juice, but does not bear a statement with appropriate prominence on the information panel of the total percentage of such fruit or vegetable juice contained in the food.
INCONSPICU
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(f) of the FD&C Act in that any word, statement, or other information required by or under the authority of the FD&C Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary terms of purchase and use (for example, label contains information in two or more languages but fails to repeat all required information in both languages in accordance with 21 CFR 101.15(c)(2), or label fails to include all required information in English in accordance with 21 CFR 101.15(c)(1), except in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English)).
MFR INSAN
The article is subject to refusal of admission pursuant to section 801(a)(1) in that the article appears to have been manufactured, processed, or packed under insanitary conditions.
NO ENGLISH
Required label or labeling appears to not be in English in violation of 21 C.F.R. 801.15(c)(1)
LACKS FIRM
The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
LACKS N/C
The article is in package form and appears to not have a label containing an accurate statement of the quantity of the contents in terms of weight, measure or numerical count and no variations or exemptions have been prescribed by regs.
EXPIRED
the product strength differs from, or its purity or quality falls below, that which it purports or is represented to possess in that it is past its labeled expiration date.
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 10/23/2025 | 62GRY99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 7/31/2025 | 66XDY99HOMEOPATHIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/31/2025 | 66XDY99HOMEOPATHIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/28/2025 | 62GRL99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/23/2025 | 66XKL99HOMEOPATHIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/13/2025 | 65CPY99NUTRIENT/TONIC N.E.C. | 72NEW VET DR | Division of Southeast Imports (DSEI) |
| 5/13/2025 | 65CPY99NUTRIENT/TONIC N.E.C. | 72NEW VET DR | Division of Southeast Imports (DSEI) |
| 4/29/2025 | 54FNY01ACONITE (HERBAL & BOTANICALS, NOT TEAS) | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 4/9/2025 | 66VIY99MISCELLANEOUS PATENT MEDICINES, ETC. | Division of Southeast Imports (DSEI) | |
| 4/9/2025 | 66VIY99MISCELLANEOUS PATENT MEDICINES, ETC. | Division of Southeast Imports (DSEI) | |
| 12/3/2024 | 55YY99PHARMACEUTIC NECESSITIES AND CONTAINERS, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/2/2024 | 66VCY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 7/23/2024 | 66VBY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/16/2024 | 66YBJ99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | Division of Southeast Imports (DSEI) | |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAL99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/24/2024 | 56YAE99ANTIBIOTIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/26/2024 | 62GOK99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/29/2024 | 66VRY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Northern Border Imports (DNBI) |
| 1/29/2024 | 66VQY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Northern Border Imports (DNBI) |
| 12/26/2023 | 66VRY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 12/26/2023 | 66VQY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 11/2/2023 | 62GPE99ANTI-INFLAMMATORY N.E.C. | Division of Northern Border Imports (DNBI) | |
| 10/27/2023 | 54YCY99VITAMIN, MINERAL, PROTEINS AND UNCONVENTIONAL DIETARY SPECIALITIES FOR HUMANS AND ANIMALS, N.E.C. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 6/2/2023 | 55QP19PETROLATUM (PHARMACEUTIC NECESSITY - OINTMENT BASE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/24/2023 | 60CCL48OXYMETAZOLINE HCL (ADRENERGIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/4/2021 | 64DBY99EMOLLIENT, LUBRICANT, N.E.C. | Division of Southeast Imports (DSEI) | |
| 8/19/2021 | 66VQY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/19/2021 | 66VRL99MISCELLANEOUS PATENT MEDICINES, ETC. | Division of Northern Border Imports (DNBI) | |
| 4/19/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 4/19/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 4/19/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 4/19/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 4/19/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 4/19/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 3/5/2021 | 62GBL99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of West Coast Imports (DWCI) |
| 2/21/2021 | 66YDK99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Southwest Imports (DSWI) |
| 1/19/2021 | 66VCY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/14/2020 | 66VBK99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Northern Border Imports (DNBI) |
| 11/13/2020 | 61LAY30HEPARIN CALCIUM (ANTI-COAGULANT) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/17/2020 | 62GBJ99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/17/2020 | 65RCL99REPLENISHER N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/17/2020 | 64BCL99DIURETIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/13/2020 | 66VAY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/12/2019 | 62GAJ99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/1/2017 | 66VCY99MISCELLANEOUS PATENT MEDICINES, ETC. | 27DRUG GMPS | Division of Southeast Imports (DSEI) |
Frequently Asked Questions
What is Biologische Heilmittel Heel Gmbh's FDA import refusal history?
Biologische Heilmittel Heel Gmbh (FEI: 3002806504) has 172 FDA import refusal record(s) in our database, spanning from 11/30/2001 to 10/23/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Biologische Heilmittel Heel Gmbh's FEI number is 3002806504.
What types of violations has Biologische Heilmittel Heel Gmbh received?
Biologische Heilmittel Heel Gmbh has been cited for 21 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Biologische Heilmittel Heel Gmbh come from?
All FDA import refusal data for Biologische Heilmittel Heel Gmbh is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.